Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10
Morgan Stanley has reiterated its "Hold" rating for Absci Corp (ABSI.US) and increased the stock's target price to $10. This indicates a maintained neutral stance while acknowledging potential for a higher valuation.
Absci (NASDAQ:ABSI) Shares Gap Up - Should You Buy?
Absci (NASDAQ:ABSI) shares gapped up, opening at $9.42 after closing at $8.85, and later traded near $9.64. The company, which applies AI and synthetic biology for protein-based therapeutics, has a "Moderate Buy" consensus from analysts with an average price target of $13.43, despite missing recent earnings estimates and remaining unprofitable. Institutional investors hold over 52% of the shares, showing significant interest in the company.
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10
Morgan Stanley has reiterated its "Hold" rating for Absci Corp (ABSI.US) and has increased its target price for the stock to $10. This indicates a continued neutral stance on the company's stock while acknowledging a potentially improved outlook.
ABSI Looks 1092.2% Overvalued on GF Value™
Absci Corp (NASDAQ: ABSI) reported Q2 revenue significantly below analyst expectations, yet its CEO highlighted promising interim results from its HEADLINE trial. Despite a GF Score of 46/100, indicating mixed fundamentals and challenges in profitability, insider activity shows net buying. The company's Price-to-Sales ratio of 918x is extremely high, and the GF Value™ estimates it as 1092.2% overvalued, suggesting high investor expectations for future growth amidst current losses.
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts
Absci Corporation (NASDAQ:ABSI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $13.43. Despite missing quarterly earnings and revenue estimates, institutional investors hold over 52% of the stock. The company leverages machine learning and synthetic biology in its Integrated Drug Creation® platform for developing protein-based therapeutics.
Will Absci (NASDAQ:ABSI) Spend Its Cash Wisely?
This article analyzes Absci's financial health, specifically its cash burn rate and cash reserves, to assess its ability to fund operations and future growth. It examines the company's current cash runway, which is estimated to be over two years based on recent expenditures. The analysis suggests that while Absci has a substantial cash position, it will need to manage its spending effectively to avoid needing to raise additional capital in the near future.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Absci Corp (ABSI.US), maintaining a price target of $11. This indicates the firm's continued positive outlook on the company's stock performance.
Why Absci (ABSI) Is Up 14.0% After Positive Early ABS-201 Hair Loss Data And Endometriosis Plans
Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This dual focus and long-acting profile could significantly expand Absci's market opportunities, though the company continues to face financial strain with substantial net losses.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained a target price of $16. This indicates continued confidence from the firm in the company's stock performance.
Absci Corp. Earnings Call Highlights ABS-201 And Cash
Absci Corp.'s Q2 earnings call highlighted promising interim Phase I data for its flagship antibody ABS-201, showing favorable safety, tolerability, and a long half-life. The company's financial position has been significantly strengthened by a recent $100 million financing, including a $40 million strategic investment from Eli Lilly, providing a cash runway into 2028. Absci outlined clear clinical milestones for ABS-201 in pattern hair loss and endometriosis, targeting multi-billion dollar markets while acknowledging that efficacy and durability still need to be fully proven in future unblinded data readouts.
BTIG Research Reiterates Buy Rating for Absci (NASDAQ:ABSI)
BTIG Research has reaffirmed its "Buy" rating for Absci (NASDAQ:ABSI) and set a $13.00 price target, suggesting a potential upside of over 38%. This aligns with the overall positive sentiment from analysts, with eight recommending a "Buy" and one a "Sell," leading to a "Moderate Buy" consensus. Despite a recent earnings miss where Absci reported an adjusted loss of $0.21 per share and lower-than-expected revenue, institutional investors have shown increased interest, with significant stake purchases by firms like BlackRock Inc. and State Street Corp.
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating
TD Cowen has reiterated its Buy rating for Absci Corp (ABSI.US). The firm did not specify any changes to its price target in this update.
ABSI Archives
This page provides news and articles related to Absci Corp (ABSI), a company specializing in generative AI for drug discovery. It highlights Absci's stock data and features an article discussing a major IPO targeting the healthcare AI sector, which could influence companies like Absci. The page also includes other trending investment news and financial advice.
Absci Q2 Loss Narrows, Revenue Declines
Absci reported a narrower Q2 net loss of $25.2 million, or $0.23 per share, compared to $27.9 million, or $0.26 per share, in the prior year. Revenue for the quarter declined to $0.4 million from $1.9 million year-over-year. The company's cash and cash equivalents stood at $121.2 million as of June 30, 2026.
Why is Absci stock tumbling today?
Absci Corp (ABSI) stock tumbled 16.6% in after-hours trading after the company reported second-quarter 2026 financial results that significantly missed revenue and earnings expectations. Q2 revenue was $300,000, half of the previous year's $600,000 and well below the $1.01 million consensus estimate, while the per-share loss of $0.21 exceeded the anticipated $0.19 loss. Despite the CEO highlighting positive clinical trial data, investors focused on the financial shortfall, causing a recalibration of expectations for the stock.
Absci Corp 2026: Revenue $318K, EPS ($0.21) — 10-Q Summary
Absci Corp (ABSI) reported its Q2 2026 results, showing partner program revenue of $318K, a net loss of ($33.21M), and a diluted loss per share of ($0.21). The decline in revenue is attributed to milestone timing, while the company continues to invest in its AI-designed biologics programs, with cash reserves of $201.1M supporting over 12 months of operations.
Absci Releases Q2 2026 Financial Results
Absci Corporation (ABSI) announced its Q2 2026 financial results, reporting a wider-than-expected loss of $0.21 per share against an estimated $0.20 loss. Revenue reached $318,000, significantly missing the $931,670 estimate and marking a 46.0% year-over-year decline. The company posted a net loss of $33.2 million for the quarter, with cash, cash equivalents, and marketable securities at $201 million.
Absci (NASDAQ:ABSI) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Absci (NASDAQ:ABSI) reported its quarterly earnings, missing analyst expectations with a loss of $0.21 per share against a consensus of $0.19, and revenue of $0.32 million, significantly below the $0.89 million forecast. Despite the financial miss, the company highlighted promising interim Phase 1 results for ABS-201 and upcoming clinical milestones for hair loss and endometriosis, along with extended financial runway due to a $40 million investment from Eli Lilly and recent financing. Analysts largely maintain a "Buy" rating with an average price target of $13.43, but caution that commercial success relies on unproven clinical outcomes.
Absci Corporation (NASDAQ: ABSI) boosts cash to $201M while net loss deepens
Absci Corporation reported a widening net loss of $33.2 million for Q2 2026 and $62.8 million for the first half of 2026, primarily due to increased R&D spending on its lead antibody ABS-201. Despite declining partner program revenue, the company significantly strengthened its balance sheet by raising approximately $93.6 million net from a June 2026 public equity offering, bringing its cash reserves to $201.1 million, which management expects will fund operations for at least 12 months. Interim Phase 1 data for ABS-201 in pattern hair loss showed good tolerability and a long half-life, with proof-of-concept data anticipated in late 2026 and early 2027.
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Absci announced its business updates and financial results for the second quarter of 2026. The company achieved several key milestones, including advancements in its AI drug discovery platform and strategic partnerships. Absci is focused on leveraging its technology to accelerate drug development and generate value for shareholders.
Absci set to report earnings as partnership revenue surges
Absci Corp. is preparing to announce its second-quarter results, with analysts expecting a significant surge in revenue driven by recent partnership deals, despite a disappointing first quarter. Investors will be closely watching the AI-powered drug discovery company's ability to maintain revenue momentum from its pharma collaborations and progress on its internal pipeline. Wall Street maintains a bullish outlook on Absci, with a strong buy rating from most analysts, highlighting the importance of sustained partnership revenue and its cash position for future profitability.
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Absci Corporation reported positive interim Phase 1 data for ABS-201 from its HEADLINE™ trial, demonstrating a favorable safety profile and a long half-life. The company also completed a $100 million offering, including a strategic investment from Eli Lilly & Company, extending its cash runway into the second half of 2028. Absci anticipates further proof-of-concept data for ABS-201 in pattern hair loss later this year and plans to initiate a Phase 2 trial for endometriosis in Q4 2026.
Earnings To Watch: Absci Corp (ABSI) Q2 2026 -- GF Value Sees 92% Downside
Absci Corp (NASDAQ:ABSI) is expected to report its Q2 2026 earnings on August 11, 2026, with revenue estimated at $1.17 million and earnings at $-0.2 per share. Despite an average analyst target price suggesting a 55.38% upside, GuruFocus's GF Value indicates a significant 91.71% downside from the current price of $8.93. The company's Q1 2026 revenue missed estimates by a large margin, although earnings per share beat expectations.
Earnings To Watch: Absci Corp (ABSI) Q2 2026 -- GF Value Sees 92% Downside
Absci Corp (ABSI) is scheduled to release its Q2 2026 earnings on August 11, 2026, with revenue estimates at $1.17 million and earnings at $-0.2 per share. While analyst price targets suggest a significant upside, GuruFocus's GF Value indicates a substantial downside of over 91% from the current price. The company's previous quarter results missed revenue expectations but beat earnings estimates, leading to a slight stock increase.
Absci Corp (ABSI) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Absci Corp (ABSI), detailing its current earnings forecast score, average price target from analysts, and analyst ratings. It highlights that 10 analysts generally recommend a "Buy" for ABSI, with a target price of $9.00 and an expected next-quarter revenue of $1.17M. The article also includes a peer comparison and answers FAQs regarding future revenue, price targets, and past EPS performance.
Absci Corp (ABSI) Stock News Today
This article from TradingKey provides current stock information for Absci Corp (ABSI), a biotechnology and medical research company. It includes the stock's current price, daily change, market capitalization, and indicates that more news, earnings, analyst ratings, and key developments will be available soon.
Earnings Preview: Absci Corp to Report Financial Results Post-market on August 11
Absci Corp (ABSI) is scheduled to report its financial results post-market on August 11. Analysts expect the company to post a GAAP EPS of -$0.17 for the second quarter, with revenue projections around $2.31 million. The article provides details on the company's past earnings performance and stock price movements following previous announcements.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating for Absci Corp (ABSI.US) and maintained a target price of $16. This indicates the firm's continued confidence in the company's stock performance. Investors will likely view this as a positive signal regarding Absci's future outlook.
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $13
BTIG has reaffirmed its Buy rating for Absci Corp (ABSI.US) and maintained its price target of $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Absci Corporation Revenue Breakdown – BOATS:ABSI
Absci Corporation (ABSI) generated $2.80 million USD in revenue last year, primarily from its Antibody-based Therapeutics segment. This represents a decrease from the previous year's $4.53 million USD. The United States was the company's largest regional contributor to revenue.
Absci Corp (ABSI) Cash Flow
This article provides a detailed historical cash flow statement for Absci Corp (ABSI), covering operating, investing, and financing activities on a quarterly and annual basis. It includes key financial metrics like operating cash flow, net income, capital expenditures, and free cash flow over several fiscal years. The article also features an FAQ section defining different types of cash flow and explaining their significance for investors.
Absci Corp (ABSI) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Absci Corp (ABSI), noting its current valuation score of 6.20 and ranking within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -9.18, indicating a significant deviation from its recent high and low. The report also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Absci Corp (ABSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Absci Corp (ABSI), detailing its price momentum score, current trading range, and support/resistance levels. It also presents an analysis based on various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, offering a neutral signal for the stock. The document clarifies common technical analysis terms and provides FAQs about its application to Absci Corp.
ABSI|Absci Corp|Price:7.560|Chg%:-0.510
This article provides a detailed overview of Absci Corp (ABSI), a clinical-stage biopharmaceutical company utilizing AI for therapeutic design. It covers the company's background, business scope, key financial data, and market performance. The content includes executive information, shareholding details, and institutional ownership statistics.
Absci Corp (ABSI) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Absci Corp (ABSI), identifying major institutional holders and their proportion of shares. It breaks down shareholder types and provides a historical view of institutional holdings and recent shareholder activity with changes in their positions. The article also lists various ETFs that hold Absci Corp stock.
Absci Corp (ABSI) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Absci Corp (ABSI) stock, focusing on its dividend history and stock splits. It states that Absci Corp has not distributed any dividends over the past five years. The article also includes current market data such as the stock price, market cap, and P/E ratio.
Absci Corp ABSI Income Statement
This TradingKey article provides a detailed quarterly and annual income statement for Absci Corp (ABSI), including metrics like total revenue, operating expenses, net income, and EPS. It shows that Absci Corp reported 215.00K in revenue and -29.60M in net income for the most recent quarter. The article also includes FAQs explaining how to interpret the income statement and key financial figures for the company.
Absci Corp ABSI Balance Sheet
This article provides a detailed balance sheet for Absci Corp (ABSI), presenting quarterly and annual financial data spanning several years for various asset, liability, and equity categories. It includes key financial metrics and a YoY percentage change for each item, allowing for an in-depth analysis of the company's financial health, liquidity, and leverage. The content also features an FAQ section addressing common questions about balance sheet analysis for ABSI stock.
Absci Corp (ABSI) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Absci Corp (ABSI), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company ranks 154th in the Biotechnology & Medical Research industry, with analysts generally recommending a "Buy" for its stock. The report also includes expected revenue and EPS for upcoming quarters.
ABSI|Absci Corp|Price:7.560|Chg%:-0.510
Absci Corp (ABSI) closed at $7.560, down 6.32%, with a market capitalization of $1.17 billion. The company, a clinical-stage biopharmaceutical firm, leverages AI and synthetic biology in its Integrated Drug Creation platform to design therapeutics, including pipeline programs ABS-101 for IBD and ABS-201 for hair regrowth. Analysts currently rate ABSI as a "Buy" with a target price of $13.88, representing a potential upside of 71.93%.
ABSI|Absci Corp|Price:7.953|Chg%:+0.393
TradingKey provides a comprehensive stock analysis for Absci Corp (ABSI), highlighting its "fairly valued" status within the Biotechnology & Medical Research industry and significant growth potential. Despite a recent weak stock market performance, multiple analysts rate it as a Buy with an upside potential of 83.53%. The company is in a growing phase, evidenced by a $2.80M annual income and high institutional ownership, including a significant stake by Catherine Wood.
Siren L.L.C. Takes $5.40 Million Position in Absci Corporation $ABSI
Siren L.L.C. acquired a new stake of 1.8 million shares, valued at $5.4 million, in Absci Corporation during the first quarter, representing about 1.15% of the company. Institutional ownership in Absci remains high at 52.05%, with major firms like ARK Investment Management, Vanguard, and State Street increasing their holdings. Despite missing revenue estimates, Absci beat EPS expectations in its latest quarter, and Wall Street analysts generally maintain a "Moderate Buy" rating with an average target price of $13.43.
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Moderate Buy" by Brokerages
Absci Corporation (NASDAQ:ABSI) has received an average recommendation of "Moderate Buy" from brokerages, with eight analysts rating it a buy and one a sell, and an average 12-month price target of $13.43. Despite a recent downgrade to "sell" by Wall Street Zen, other firms like HC Wainwright, BTIG Research, and Needham have increased their price targets. The company reported a smaller-than-expected quarterly loss but revenue significantly missed estimates, and it continues to face negative profitability metrics.
Absci (NASDAQ:ABSI) Stock Price Down 7.6% - Should You Sell?
Absci (NASDAQ:ABSI) shares dropped 7.6% in mid-day trading following a period of mixed analyst sentiment, despite some analysts raising price targets and maintaining buy ratings. The company's recent earnings report showed better-than-expected EPS but significantly missed revenue estimates, with profitability remaining deeply negative. Institutional investors have been adjusting their positions in Absci, and the stock currently holds an average "Moderate Buy" rating among analysts.
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci Corporation, a clinical-stage biopharmaceutical company, announced it will report its second-quarter 2026 financial and operating results on August 11, 2026, after market close. This will be followed by a webcast conference call at 4:30 p.m. ET to discuss business developments and outlook. The company is advancing its Integrated Drug Creation™ platform, which uses generative AI to design biologics, and is developing its own pipeline, including ABS-201 for hair regrowth and endometriosis treatment.
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci Corporation, a clinical-stage biopharmaceutical company, announced it will report business updates and financial results for the second quarter of 2026 after market close on Tuesday, August 11, 2026. A conference call and webcast will follow the announcement to discuss developments and outlook. The company is advancing drug discovery using generative AI and its Integrated Drug Creation™ platform.
Absci to report Q2FY26 results on August 11, 2026
Absci Corporation will release its Q2FY26 financial results and host a conference call on August 11, 2026, to discuss its business updates, financial performance, and future outlook. The clinical-stage biopharmaceutical company, which utilizes generative AI for drug design, is advancing its pipeline, including ABS-201™ for androgenetic alopecia and endometriosis. The conference call will be webcast live on the company's investor relations website.
Absci sets 4:30 p.m. ET webcast for its Aug. 11 Q2 update
Absci (Nasdaq: ABSI) will report its second quarter 2026 financial and operating results on Tuesday, August 11, 2026, after market close. Management will host a webcasted conference call at 4:30 p.m. Eastern Time to discuss business developments, financial performance, and outlook. The webcast will be accessible live and for replay on the company's investor relations website.
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci Corporation (Nasdaq: ABSI) announced its plan to report business updates and financial and operating results for the second quarter of 2026 after market close on Tuesday, August 11, 2026. The company will also host a conference call and webcast to discuss its business developments, results, and outlook. Absci is a clinical-stage biopharmaceutical company leveraging generative AI for drug discovery, including its ABS-201™ therapeutic for androgenetic alopecia and endometriosis.
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Wall Street analysts predict a 28.3% upside for Absci Corporation (ABSI), with an average price target of $13.6 and a standard deviation indicating general agreement. While price targets alone are not a reliable investment guide due to potential optimism and business incentives, ABSI's strong consensus on improved earnings estimates and a Zacks Rank #2 (Buy) suggest a solid upside potential. Investors are advised to use price targets cautiously and consider other fundamental factors.
